R&D/Clinical Trials

Having proved its efficacy against COVID-19, mRNA technology is positioned to combat another insidious human adversary: cancer.

Leveraging RWD can lessen the strain normally put on investigators and sites.

COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.

aTyr Pharma’s Dr. Sanjay S. Shukla talks about how his background in biostatistics, informatics and medicine is helping him and his team of researchers and scientists develop meaningful new medicines in a novel area of immunobiology, by looking at pathways where other drugs may have failed.

MIDD can pave new road for drug development.

Mark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.

With a background in pharma and biotech, ImmunoGen president and CEO Mark Enyedy discusses his dedication to oncology and the lessons he’s learned along the way.

AstraZeneca’s Mina Makar and Amgen’s Kave Niksefat talk about how the two companies worked together to develop the new asthma treatment, tezepelumab.

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.

With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.

How Gilead readied remdesivir for the COVID challenge.

Inside Regeneron’s monoclonal antibody development to treat COVID.

Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.

Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.

College roommates, industry partnerships help bring Pfizer vaccine to fruition.

The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.

The field of longevity therapeutics — with the goal “of not just adding years to life but adding life to years” — is already disrupting the medical industry, writes Marco Quarta.

Annovis Bio's Maria L. Maccecchini, Ph.D., talks about why she, as a scientist and biotech company entrepreneur, became focused on protecting nerve cells in the brain and in the body, as a way to treat neurodegenerative disease.

Pascal Descargues, Ph.D., founder of Genoskin, talks about how the company is responding to the US government’s push to help pharma and biotech leaders speed clinical drug development and testing.

Insights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.

The shift to clinical-grade support offers great opportunity.

Dr. Matthias Schmidt talks about his new role leading the US subsidiary of Japan’s JCR Pharmaceuticals after a “far-from-easy” merger last year.

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.

Francesca Properzi and Sudip Sinha talk about how the results of an inaugural Clinical Trial Digital Tracker Survey indicate that many clinical trials organizations are still reluctant to integrate digital technologies into their processes.

Decentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.